9 results about "Benign tumor" patented technology

The invention relates to the technical field of image recognition, in particular to an osteosarcoma image intelligent recognition and classification method and system based on an image recognition model. The method comprises the following steps: collecting a tumor image and carrying out multi-sequence disturbance equilibrium enhancement to generate an enhanced block tumor image, then obtaining a color standardized image through color space transformation remapping, then extracting a tumor region image and carrying out contrast inversion processing, reconstructing a tumor feature image, and finally, carrying out multi-sequence disturbance equilibrium enhancement on the tumor feature image. Based on a preset image recognition model, tumor edge features are recognized, the edge rule degree is determined, preliminary classification is carried out, a benign tumor image is obtained, surrounding metabolite signal features of the benign tumor image are analyzed, a benign reference group is formed through combination, metabolism state comparison is carried out on tumor feature images, and metabolism difference data are generated. And performing category correction according to the metabolic state mapping data so as to identify the osteosarcoma category. According to the invention, intelligent analysis of tumor features is realized, the image processing flow is optimized, and the processing efficiency is improved.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor / —inactivator and α-lipoic acid and / or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and α-lipoic acid and / or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

The invention relates to the technical field of image recognition, and discloses a breast ultrasonic tumor recognition method fusing channel attention and dynamic channel routing, which comprises the following steps: acquiring a breast ultrasonic image, and carrying out preprocessing and data enhancement; constructing a deep convolutional neural network containing a ResNet101 backbone network, an SE channel attention unit and a dynamic feature reconstruction module; taking Focal Loss with category weight as a loss function, and combining with an SAM optimizer to train the network; according to the method, an SE channel attention unit is embedded, a dynamic feature reconstruction module is connected, and an SAM optimizer is cooperatively used, so that the model can model channel importance and global space context dependence at the same time, and the classification probability of a benign tumor, a malignant tumor or a normal tissue is output. And a flat minimum value is found on a complex loss curved surface, so that accurate and robust recognition of tumors in low-quality and small-sample breast ultrasound images is realized, and the classification accuracy and generalization ability are effectively improved.

The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and / or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.

The application provides a malignant and benign tumor recognition system based on a hyperspectral image, and relates to the technical field of medical image processing.The system comprises: a feature extraction module, which is used for performing sharpening processing on an acquired hyperspectral image and extracting an edge feature map of the hyperspectral image after the sharpening processing; a feature fusion module, which is used for performing fusion of different frequency band features of the hyperspectral image and the edge feature map by using a Laplacian pyramid image fusion algorithm to obtain a tumor hyperspectral feature enhancement map; and a recognition module, which is used for inputting the tumor hyperspectral feature enhancement map into a pre-trained malignant and benign tumor recognition model, outputting tumor boundary features, and determining a tumor category of the hyperspectral image according to the tumor boundary features.Through the system, more abundant tumor edge information can be extracted, the tumor recognition performance in the case that the malignant tumor is not obvious is strengthened, and thus the accuracy of the malignant and benign tumor recognition is improved.

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

The present application relates to the technical field of medical teaching aids, in particular to a breast cancer pathological demonstration teaching aid, which comprises a base and two models rotating on the base, the two models are symmetrically designed, the two models are folded to form a chest model, and the two models can be installed and adjusted with internal tissue devices when unfolded; a functional inner cavity is formed in the inside of the model, an assembly plate is installed in the functional inner cavity, a capsule is installed on the assembly plate, the capsule is a semi-elliptical shell, the capsule is hollow, and a reaction medium capable of hardening or softening is designed in the capsule; a variable assembly, the reaction medium can be driven to be solid or liquid by the variable assembly to simulate malignant or benign tumors, and the present application can simulate palpation of the activity, adhesion, hardness and size of the lump.